失代偿期肝硬化患者血栓的预防与治疗
本文综述失代偿期肝硬化患者抗凝治疗的三个常见临床场景:房颤伴基线INR升高、房颤抗凝期间复发出血、门静脉血栓伴血小板减少。文中讨论现有文献并提出管理策略,指出因肝脏代谢改变及关键随机试验排除肝硬化患者,最佳抗凝实践仍具挑战。
要点
- 失代偿期肝硬化患者常有抗凝指征,包括房颤卒中预防和静脉血栓栓塞防治。
- 肝硬化患者抗凝率随时间改善,但出血顾虑和关键试验排除仍使最佳实践不明确。
- 综述针对三个常见场景讨论文献并提出管理方法。
核心结论
- 失代偿期肝硬化患者抗凝管理因出血风险及证据缺乏而具挑战,需针对具体场景个体化决策。
研究设计与样本
- 综述,讨论失代偿期肝硬化患者需考虑抗凝的三个常见临床场景并基于文献提出管理方法。
主要发现
- 有抗凝指征的肝硬化患者抗凝率随时间改善。
- 肝病改变抗凝药肝脏清除,增加出血顾虑。
- 直接口服抗凝药和华法林的关键随机试验排除了肝硬化患者。
临床怎么用
- 对失代偿期肝硬化合并房颤或门静脉血栓患者,应评估抗凝指征并参考本文场景化建议个体化决策。
局限性
- 关键随机试验排除肝硬化患者,直接证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with decompensated cirrhosis commonly have indications for anticoagulation, including stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolism, particularly portal vein thrombosis. While the rates of anticoagulation in those with indications for therapy have improved over time, the concern for bleeding due to altered hepatic elimination of anticoagulants and exclusion of patients with cirrhosis from pivotal randomized trials of direct oral anticoagulants and warfarin continue to create challenges in defining best practices for anticoagulation in patients with cirrhosis, especially in decompensated disease. In this review, we present 3 commonly encountered clinical scenarios in patients with decompensated cirrhosis requiring consideration of anticoagulation: a patient with atrial fibrillation and elevated baseline international normalized ratio, a patient with atrial fibrillation and recurrent bleeding while on anticoagulation, and a patient with portal vein thrombosis and thrombocytopenia. For each scenario, we discuss the available literature and propose a management approach.
引用
- Bell C, Afzal A, Carlin S, et al. Prevention and treatment of thrombosis in patients with decompensated cirrhosis. J Thromb Haemost. 2026. PMID: 41520803. doi:10.1016/j.jtha.2025.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。